1338810-01-7

Upstream product

• 332386-74-0 (-)-(2R,3R)-cis-5,7-bis(benzyloxy)-2-[3,4,5-tris(benzyloxy)phenyl]chroman-3-ol 
• 25458-44-0 4-(methoxymethoxy)benzoic acid 
• 1338809-99-6 (2R,3R)-5,7-diacetoxy-2-(3,4,5-triacetoxyphenyl)-chroman-3-yl 4-(methoxymethoxy)benzoate 
• 1338809-98-5 (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-chroman-3-yl 4-(methoxymethoxy)benzoate 
• 1338809-96-3 (2R,3R)-5,7-bis(benzyloxy)-2-(3,4,5-tris(benzyl-oxy)phenyl)chroman-3-yl 4-(methoxymethoxy)benzoate 

Downstream Products

• 1338809-86-1 (2R,3R)-5,7-diacetoxy-2-(3,4,5-triacetoxyphenyl)-chroman-3-yl 4-(phosphoryloxy)benzoate 
• 1338810-03-9 (2R,3R)-5,7-diacetoxy-2-(3,4,5-triacetoxyphenyl)-chroman-3-yl 4-(dibenzyloxyphosphoryloxy)benzoate 

Relevant academic research and scientific papers

Epigallocatechin gallate derivatives preparation method

The invention mainly aims at achieving lipid-solubility transformation of epigallocatechin gallate which is polyhydroxy, good in water solubility and low in bioavailability, including three ways, namely encapsulating hydroxyl with different anhydrides so

Synthesis of phosphates and phosphates-acetates hybrids of green tea polyphenol (-)-epigallocatechine-3-gallate (EGCG) and its G ring deoxy analogs as potential anticancer prodrugs

A series of phosphate or phosphate-acetate hybrid modified EGCG or EGCG G ring deoxy analogs were synthesized by a convenient semi-synthesis strategy from the abundant natural compound EGCG.